-

IPA to Present at Jefferies Healthcare Conference 2023

VICTORIA, British Columbia--(BUSINESS WIRE)--ImmunoPrecise Antibodies Ltd. (NASDAQ: IPA) (“ImmunoPrecise” or “IPA” or the “Company”) an AI-driven biotherapeutic research and technology company today announced that Dr. Jennifer Bath, the company's Chief Executive Officer and President, will present at the Jefferies Healthcare Conference on Friday June 9, 2023, at 11:00 a.m. Eastern time.

The live and archived webcast of the presentation will be accessible from the company’s website at https://ir.ipatherapeutics.com/events-and-presentations/default.aspx. The replay of the webcast will be available for 90 days.

About ImmunoPrecise Antibodies Ltd.

ImmunoPrecise Antibodies Ltd. has several subsidiaries in North America and Europe including entities such as Talem Therapeutics LLC, BioStrand BV, ImmunoPrecise Antibodies (Canada) Ltd. and ImmunoPrecise Antibodies (Europe) B.V. (collectively, the “IPA Family”). The IPA Family is a biotherapeutic research and technology group that leverages systems biology, multi-omics modelling and complex artificial intelligence systems to support its proprietary technologies in bioplatform-based antibody discovery. Services include highly specialized, full-continuum therapeutic biologics discovery, development, and out-licensing to support its business partners in their quest to discover and develop novel biologics against the most challenging targets. For further information, visit www.ipatherapeutics.com.

Contacts

Investor: investors@ipatherapeutics.com

Industry:

ImmunoPrecise Antibodies

NASDAQ:IPA
Release Versions
EnglishFrench
$Cashtags
$IPA
$XBI
Hashtags
#AI
#BioStrand
#Omics
#antibodydiscovery
#bioinformatics
#biotechnology
#biotherapeutics
#covid19
#drugdiscovery
#futurepandemic
#omics
#personalizedmedicine
#polytope
#precisionmedicine
#variants

Contacts

Investor: investors@ipatherapeutics.com

Social Media Profiles
Facebook
Linkedin
Substack
Twitter
YouTube
More News From ImmunoPrecise Antibodies

MindWalk Validates Platform Precision with Breakthrough Discovery Targeting Pathogenic TDP-43 in Neurodegenerative Disease

VICTORIA, British Columbia--(BUSINESS WIRE)--MindWalk Holdings Corp. (“MindWalk” or the “Company”) (Nasdaq: HYFT) today announced the discovery and validation of monoclonal antibodies and intrabodies that selectively target misfolded, pathogenic TDP-43, a disease-driving protein implicated in amyotrophic lateral sclerosis (ALS), frontotemporal dementia (FTD), and certain forms of Alzheimer’s disease. The work demonstrates MindWalk’s ability to discriminate with structural precision between toxi...

REPEAT/MindWalk Advances Universal Influenza Program with a Breakthrough Functional Insight

AUSTIN, Texas--(BUSINESS WIRE)--MindWalk Holdings Corp. (NASDAQ:HYFT) (“MindWalk” or the “Company”), a Bio-Native AI therapeutic research and technology company, today announced an advance in its universal influenza program following the identification of a breakthrough functional constraint that persists across influenza viruses despite continual evolution. Using its patented HYFT® Deep Data technology, MindWalk identified a functional pattern embedded in influenza biology that remains intact...

MindWalk Advances Universal Influenza Program with a Breakthrough Functional Insight

AUSTIN, Texas--(BUSINESS WIRE)--MindWalk Holdings Corp. (NASDAQ:HYFT) (“MindWalk” or the “Company”), a Bio-Native AI therapeutic research and technology company, today announced an advance in its universal influenza program following the identification of a breakthrough functional constraint that persists across influenza viruses despite continual evolution. Using its patented HYFT® Deep Data technology, MindWalk identified a functional pattern embedded in influenza biology that remains intact...
Back to Newsroom